Dear Editor,

In intensive care settings, augmented renal clearance (ARC) is recognized as a leading cause of subtherapeutic antibiotic exposure, and piperacillin-tazobactam (PTZ) has been the most frequently studied antibiotic in this context \[[@CR1]--[@CR5]\] (Table [1](#Tab1){ref-type="table"}). We, like others, previously suggested that higher than licensed dosing regimens should be necessary for empirical treatment in patients with ARC \[[@CR4], [@CR5]\]. We thus aimed to determine the efficacy and tolerability of such a strategy.Table 1Documented rates of pharmacodynamic target non-attainment for various piperacillin dosing regimens in ARC patientsStudyPopulationPIP dosing regimen and administrationARCProbability of achieving a 100%fT~\>16mg/L~ in ARC patientsAndersen et al. \[[@CR1]\]22 non-critically ill patients4 g every 8 h\
3-min boluseCl~Cr~ \> 130 mL/min\
*N* = 4/22 (18%)In ARC patients, probability of achieving a 100%fT~\> 16 mg/L~ was 0%.Udy et al. \[[@CR2]\]48 critically ill patients4 g/0,5 g every 6 h\
20-min intermittent infusion6-h mCl~Cr~\
as continuous variableCumulative fraction of response decreased from 40% to less than 5% when Cr~CL~ values increased from 120 to 300 mL/min.Carlier et al. \[[@CR3]\]60 critically ill patients\
43 treated by PIP4 g/0,5 g every 6 h\
3-h extended infusion24-h mCl~Cr~ \> 130 mL/min\
*N* = 29/60 (48%)In ARC patients, probability of achieving a 100%fT~\> 16 mg/L~ was 24% \[*no specific data for PIP*\].Carrié et al. \[[@CR4]\]59 critically ill patients\
173 PIP plasma samples16 g/day continuously\
160 mg/mL, 12-h infusion24-h mCl~Cr~ \> 130 mL/min\
*N* = 36/59 (61%)Probability of achieving a 100%fT~\> 16 mg/L~ was 93% for 130 ≤ Cr~CL~ \< 200 mL/min and 80% for Cl~Cr~ \> 200 mL/min.Dhaese et al. \[[@CR5]\]110 critically ill patients\
270 PIP plasma samplesContinuous infusion, dosing regimen based on kidney function (16--24 g/day)8-h mCl~Cr~ \> 130 mL/min\
*N* = 77/270 (32%)The fractional target attainment for the standard dosing regimen (16 g/day) decreased from 75 to 37% when Cr~CL~ increased from 150 to 300 mL/min.*%fT*~*\> 16 mg/L*~ fraction of time spent with an unbound concentration \> 16 mg/L (representing the highest MIC for *Pseudomonas* as per the European Committee on Antimicrobial Susceptibility Testing), *ARC* augmented renal clearance, *eCl*~*Cr*~ estimated creatinine clearance (Cockroft and Gault), *mCl*~*Cr*~ measured creatinine clearance, *FTA* fractional target attainment, *MIC* minimal inhibitory concentration, *PIP* piperacillin

For this purpose, we performed a retrospective analysis of our local database over a 10-month period (February to November 2018). Ethical approval confirmed the observational design of the study (IRB number: CERAR 00010254-2018-074). Over the study period, every patient with a 24-h measured creatinine clearance (CL~Cr~) ≥ 150 mL/min received increased dosing regimens of PTZ (20/2.5 g daily after a loading dose of 4/0.5 g over 60 min) \[[@CR4]\]. Subsequent dose adjustments were guided by therapeutic drug monitoring performed between 24 and 72 h of antimicrobial therapy. As previously described, observed concentrations were corrected for protein binding (30% for piperacillin) to estimate unbound fraction \[[@CR1]\].

As MIC data are often not available to the clinician prescribing an empirical antimicrobial regimen, piperacillin underdosing was defined by an unbound concentration under 16 mg/L, representing the highest MIC for *Pseudomonas* as per the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@CR4]\]. Empirical underdosing for tazobactam was defined by an unbound concentration under 2 mg/L, representing the highest MIC for high-level β-lactamase-producing strains \[[@CR4]\]. Excessive dosing was defined as a free drug concentration above 150 mg/L \[[@CR4]\].

The final dataset consisted of 36 PTZ samples collected from 35 patients. The main characteristics and outcomes of these patients are resumed in Table [2](#Tab2){ref-type="table"}. Except for one tazobactam sample, all samples were in the therapeutic range (Fig. [1](#Fig1){ref-type="fig"}). No patient experienced excessive dosing above the supposed toxic cutoff ≥ 150 mg/L. Three of them (9%) experienced therapeutic failure or relapse \[[@CR4]\], all related to secondary acquisition of antimicrobial resistance.Table 2Characteristics of the populationVariableOverall population\
*N* = 35Demographic data - Age (years)48 \[37--57\] - Male sex31 (89) - BMI (kg/m^2^)25 \[22--29\]Admission - Polytrauma30 (86) - Non-traumatic surgery5 (14)SAPS II42 \[34--51\]Presumed/confirmed site of infection - Pulmonary infection31 (89) - Intra-abdominal infection3 (9) - Intravascular-catheter-related infection1 (3)Bacteremia2 (6)Use of vasopressors12 (34)Modified SOFA score\*3 \[1--6\]CL~Cr~ the day of therapeutic drug monitoring166 \[159--191\]Antimicrobial therapy - Duration of antibiotic therapy before TDM2 \[1--3\] - Association with aminoglycoside or quinolone8 (23) - De-escalation9 (26) - Total duration of antimicrobial therapy (days)7 \[5--7\]Type of pathogen - Enterobacteriaceae33 (94) - *Staphylococcus* spp.18 (51) - *Haemophilus influenzae*8 (23) - Non-fermenting GNB3 (9) - Other3 (9)Polymicrobial infection20 (57)Non-documented infection1 (3)PK/PD targets - Piperacillin unbound concentrations (mg/L)36.4 \[27.7--44.3\]  Empirical underdosing for piperacillin0 (0)  Excessive dosing for piperacillin0 (0) - Tazobactam unbound concentrations (mg/L)4.55 \[3.57--5.88\]  Empirical underdosing for tazobactam1 (3) - PIP/TAZ ratio9.1 \[6.9--11.1\]Clinical outcomes - Therapeutic failure before end of treatment2 (6) - Relapse after end of treatment1 (3)Secondary resistance to PTZ3 (9)MV duration (days)14 \[4--26\]ICU length of stay (days)22 \[14--37\]ICU mortality0 (0)Results expressed as median \[25--75 interquartile\] and numbers (percentage). Therapeutic failure was defined as an impaired response (persistent or recurrent fever, organ dysfunction, clinical and biological symptoms of the initial infection) with the need for escalating empirical antimicrobial therapy. Relapse was defined by a recurrent infection within 15 days after completing antibiotic therapy with at least one of the initial causative bacterial strains growing at a significant concentration from a second sample\*Sepsis-related Organ Failure Assessment score, without neurologic and renal componentsFig. 1Unbound steady-state concentrations (mg/L) of piperacillin (**a**) and tazobactam (**b**) using higher than licensed dosing regimens (20 g/day \[160 mg/mL, 10-h infusion\] after a loading dose of 4 g) in critically ill patients with ARC (Cl~Cr~ ≥ 150 mL/min the first day of antimicrobial therapy). The dotted line indicates underdosing threshold for piperacillin (fixed at 16 mg/L) and tazobactam (fixed at 2 mg/L) \[[@CR4]\]*.* The black circles indicate samples from patients who experienced therapeutic failure \[[@CR4]\]

When targeting a theoretical MIC at the upper limit of the susceptibility range, higher than licensed doses of PTZ allowed achieving the pharmacodynamic target in all patients with CL~Cr~ ≥ 150 mL/min, without excessive dosing. Further studies are warranted to confirm if such a strategy improves the rate of therapeutic success.
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:   Creatinine clearance
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:   Estimated creatinine clearance (Cockcroft and Gault)

FTA

:   Fractional target attainment
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:   Measured creatinine clearance
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PIP

:   Piperacillin

PTZ

:   Piperacillin-Tazobactam
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